Golcadomide

Summary

Golcadomide (CHEMBL5095226) is a phase-3 clinical-stage small molecule targeting CRBN; indicated across 5 conditions including diffuse large b-cell lymphoma and non-hodgkin lymphoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (CRBN)
• Indications: 5 conditions
• Clinical trials: 21
• Chemistry: 535.6 Da · C28H30FN5O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095226
Name	Golcadomide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	146195299
Molecular formula	C28H30FN5O5
Molecular weight	535.6
InChIKey	NZYDBVQXOGPDDU-QHCPKHFHSA-N

SMILES: C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=C(C2=O)C(=CC=C3)NCC4=C(C=C(C=C4)CN5CC(C5)N6CCOCC6)F

IUPAC name: 2-[(3S)-2,6-dioxopiperidin-3-yl]-4-[[2-fluoro-4-[(3-morpholin-4-ylazetidin-1-yl)methyl]phenyl]methylamino]isoindole-1,3-dione

Also known as: Cc 99282, CC-99282, CC1007548, CC99282, Golcadomida, Golcadomide, GOLCADOMIDE

Parent form; salt/anhydrous children: CHEMBL6068405

Patent coverage: 84 distinct patent families (269 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 167 (62%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CRBN	cereblon	Binding		0.2%	Q96SW2

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CRBN.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Potential therapeutics for SARS	1	CRBN

Dominant GO biological processes

GO term	Targets
protein ubiquitination	1
positive regulation of Wnt signaling pathway	1
negative regulation of protein-containing complex assembly	1
positive regulation of protein-containing complex assembly	1
negative regulation of monoatomic ion transmembrane transport	1
locomotory exploration behavior	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
limb development	1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
non-Hodgkin lymphoma	2	MONDO:0018908	EFO:0005952
follicular lymphoma	2	MONDO:0018906	MONDO:0018906
neoplasm	2	MONDO:0005070	EFO:0000616
lymphoma	1	MONDO:0005062	EFO:0000574

Clinical trials

Total trials: 21.

Phase distribution

Phase	Trials
PHASE2	7
PHASE1/PHASE2	6
PHASE1	6
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06356129	PHASE3	ACTIVE_NOT_RECRUITING	Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06911502	PHASE3	RECRUITING	A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator’s Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT03930953	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT05283720	PHASE2	RECRUITING	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05788081	PHASE2	ACTIVE_NOT_RECRUITING	Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
NCT06108232	PHASE2	ACTIVE_NOT_RECRUITING	Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
NCT06271057	PHASE2	RECRUITING	Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
NCT06425302	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06834373	PHASE2	RECRUITING	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
NCT06835530	PHASE2	RECRUITING	A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
NCT07018752	PHASE1/PHASE2	RECRUITING	A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
NCT07269639	PHASE1/PHASE2	NOT_YET_RECRUITING	Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07578077	PHASE1/PHASE2	NOT_YET_RECRUITING	Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT03310619	PHASE1/PHASE2	COMPLETED	A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
NCT06767956	PHASE1/PHASE2	WITHDRAWN	Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
NCT04884035	PHASE1	RECRUITING	Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
NCT05169515	PHASE1	RECRUITING	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT06209619	PHASE1	RECRUITING	CC-99282 + Rituximab Early Post CART for Non-Hodgkin’s Lymphoma
NCT07608731	PHASE1	NOT_YET_RECRUITING	Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
NCT04434196	PHASE1	COMPLETED	A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06363630	PHASE1	COMPLETED	A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

19 molecules share ≥1 primary target. Top 19 by shared-target count:

Molecule	Source	Status	Shared targets
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	CRBN
POMALIDOMIDE	ChEMBL + PubChem	Phase 4 (approved)	CRBN
ASCIMINIB	ChEMBL	Phase 4 (approved)	CRBN
BRIGATINIB	ChEMBL	Phase 4 (approved)	CRBN
DASABUVIR	ChEMBL	Phase 4 (approved)	CRBN
LENALIDOMIDE	ChEMBL	Phase 4 (approved)	CRBN
PONATINIB	ChEMBL	Phase 4 (approved)	CRBN
THALIDOMIDE	ChEMBL	Phase 4 (approved)	CRBN
IBERDOMIDE	ChEMBL	Phase 3	CRBN
MEZIGDOMIDE	ChEMBL	Phase 3	CRBN
URACIL	ChEMBL	Phase 3	CRBN
VEPDEGESTRANT	ChEMBL	Phase 3	CRBN
ADAVOSERTIB	ChEMBL	Phase 2	CRBN
AVADOMIDE	ChEMBL	Phase 2	CRBN
E-7820	ChEMBL	Phase 2	CRBN
FORETINIB	ChEMBL	Phase 2	CRBN
INDISULAM	ChEMBL	Phase 2	CRBN
Fulvestrant	PubChem	Approved	CRBN
Sotorasib	PubChem	Approved	CRBN